Open house Risperidone rebate agreements
Titre original de l'avis
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Risperidon in der Darreichungsform Pulver und Lösungsmittel zur Herstellung einer Injektionslösung, ATC N05AX08
Score d'opportunité
Pourquoi ce score ?
Opportunité
40 / 100
Complexité
20 / 100
Facteurs de risque
No estimated value is provided. It is unclear what the potential volume or revenue from this agreement may be.
For paper submissions, two original copies must be sent by post; electronic submissions require a qualified electronic...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Moderate opportunityFaits clés
- Framework procurement
- Supplies contract
- 1 lot
- Duration until May 2027
- Supply of the pharmaceutical product Risperidone in the form of powder and solvent for injection solution (ATC N05AX08)
- Conclusion of a non-exclusive rebate agreement with AOK Bayern
Afficher le résumé complet
This is an open-house model (not a standard procurement) by AOK Bayern for non-exclusive rebate agreements on Risperidone (powder and solvent for injection solution, ATC N05AX08). Any interested pharmaceutical company that meets the eligibility criteria can join. The agreement runs from 1 June 2025 to 31 May 2027. There is no competitive selection; contracts are concluded with all qualified suppliers. No estimated contract value is provided.
Risques
No estimated value is provided. It is unclear what the potential volume or revenue from this agreement may be.
For paper submissions, two original copies must be sent by post; electronic submissions require a qualified electronic...
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Eligibility
- Only pharmaceutical companies are eligible to participate.
Administrative
- Submission of a signed self-declaration of reliability.
- Submission of the signed contract and annex (list of medicines subject to the agreement).
Les exigences peuvent être incomplètes.
Acheteur
Localisation
München, DEU
Site web
Profil acheteur
Identifiant
DE811695320
Activité
Health
Lots (1)
LOT-0001
Open house Risperidone rebate agreements
Non-exclusive rebate agreement for Risperidone in the form of powder and solvent for injection solution. All interested pharmaceutical companies that meet the eligibility criteria can participate.
Localisation
Durée
Catégorie
Date limite
Détails des critères
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Note sur la valeur
Afficher les données TED originales
Titre original du lot
Open house Arzneimittelrabattverträge Risperidon in der Darreichungsform Pulver und Lösungsmittel zur Herstellung einer Injektionslösung, ATC N05AX08
Description TED originale
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Détails de la procédure
- Date de publication
- 15 Apr 2025
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 249452-2025
Documents (2)
Appels d'offres similaires
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Score d'opportunité
Pourquoi ce score ?
Opportunité
40 / 100
Complexité
20 / 100
Facteurs de risque
No estimated value is provided. It is unclear what the potential volume or revenue from this agreement may be.
For paper submissions, two original copies must be sent by post; electronic submissions require a qualified electronic...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications